By Billy Candra 
Scientists at The Hospital for Sick Children (SickKids) have achieved a significant breakthrough in the fight against medulloblastoma, the most prevalent malignant brain cancer in children. Their latest discovery offers a novel approach to prevent tumour growth before it even begins for a specific subtype known as sonic hedgehog (SHH) medulloblastoma, marking a potential paradigm shift in pediatric oncology. This groundbreaking research, detailed in a recent publication in Nature Communications, identifies a critical protein responsible for activating dormant cancer stem cells, thereby driving tumour formation and recurrence. By successfully inhibiting this protein in preclinical models, the team has demonstrated a compelling strategy for "cancer interception."
The Formidable Challenge of Pediatric Brain Tumours
Brain cancer in children presents a unique and particularly devastating set of challenges. Unlike many adult cancers, pediatric brain tumours often manifest with subtle, non-specific symptoms, leading to diagnoses at advanced stages when the disease has become highly complex. By this point, the intricate mechanisms underpinning tumour growth are frequently obscured, complicating targeted therapeutic efforts. Medulloblastoma, accounting for approximately 20% of all childhood brain tumours, typically originates in the cerebellum, the part of the brain responsible for balance and coordination. It primarily affects children between the ages of three and eight, though it can occur at any age. While advances in surgery, radiation, and chemotherapy have improved survival rates over the past few decades, particularly for standard-risk patients, a significant proportion of children still face aggressive recurrence or suffer debilitating long-term side effects from intensive treatments, including cognitive impairments, endocrine dysfunction, and secondary cancers. For high-risk groups, the prognosis remains grim, underscoring the urgent need for more effective and less toxic therapies.
The SHH subtype, which accounts for roughly 30% of all medulloblastoma cases, is characterized by aberrations in the sonic hedgehog signaling pathway, a crucial developmental pathway that, when dysregulated, can drive uncontrolled cell proliferation. Despite targeted therapies being available for this subtype, resistance and recurrence remain significant hurdles, often driven by residual, treatment-resistant cells.
The Enigma of Cancer Stem Cells and Recurrence
At the heart of many aggressive cancers, including medulloblastoma, lies a population of highly resilient cells known as cancer stem cells (CSCs). These cells possess properties similar to normal stem cells: the ability to self-renew, differentiate into various cell types within the tumour, and initiate new tumour growth. Crucially, CSCs are often resistant to conventional therapies like chemotherapy and radiation, allowing them to survive treatment, lie dormant, and later "reawaken" to drive tumour recurrence. This phenomenon is a primary reason why even seemingly successful treatments can be followed by a devastating relapse.
For years, Dr. Peter Dirks, a Senior Scientist in the Developmental, Stem Cell & Cancer Biology program and Chief of the Division of Neurosurgery at SickKids, has been a leading pioneer in the study of cancer stem cells. His lab has been dedicated to unraveling the fundamental mechanisms that govern these elusive cells, particularly in the context of brain tumours. His previous work, including a recent study published in Nature describing the early stages of glioblastoma development, has consistently focused on understanding the origins and drivers of these malignant cells, paving the way for targeted interventions. The current study builds upon this foundation, zeroing in on the specific processes that rouse dormant stem cells in SHH medulloblastoma.
Unveiling the ‘Awakening’ Mechanism: The Role of OLIG2
The research team, spearheaded by Dr. Dirks and first author Dr. Kinjal Desai, a postdoctoral researcher in the Dirks lab, embarked on a meticulous investigation into the cellular transitions that orchestrate the development of SHH medulloblastoma tumours. Their approach combined cutting-edge genomic analyses with sophisticated functional experiments in preclinical models, allowing them to map the molecular events occurring during the earliest stages of tumourigenesis and post-treatment relapse.
Their persistent efforts led to a pivotal discovery: a specific protein, identified as OLIG2, plays a critical role in activating ‘sleeping’ stem cells. These dormant stem cells, which otherwise remain quiescent, are spurred into division and growth by OLIG2, thereby initiating tumour formation or driving the regrowth of residual disease after conventional treatments. The researchers found that OLIG2 essentially acts as a molecular "alarm clock," rousing these dangerous cells from their slumber. This finding is particularly significant because it points to a defined, targetable event in the cancer’s life cycle. "There is order to how the cancer initiating stem cells undergo fate changes to form tumours," Dr. Desai explains. "We can target an early transition event and intercept the entire process – essentially stopping the cancer in its earliest form."
This insight into the "order" of cancer progression is a cornerstone of the cancer interception strategy. By understanding the precise moment and mechanism by which stem cells become active, researchers can design interventions that disrupt this process before it gains momentum.
Introducing CT-179: A Strategy for Cancer Interception
With the identification of OLIG2 as a key driver, the team then sought a way to neutralize its activity. Their investigation led them to a small molecule called CT-179, which demonstrated the ability to disrupt the OLIG2 protein. The critical hypothesis was that by blocking OLIG2 with CT-179, they could prevent the ‘sleeping’ stem cells from waking up, thereby stopping tumour growth in its tracks.
The preclinical studies yielded remarkable results, showcasing the dual potential of CT-179 as a therapeutic agent:
- Preventing Tumour Formation: For early-stage SHH medulloblastoma, CT-179 administered proactively prevented tumours from forming altogether. This preventative capacity is a groundbreaking aspect of the discovery, suggesting a potential future where high-risk individuals could receive early intervention. The studies demonstrated a significant increase in survival rates in the preclinical models treated with CT-179.
- Preventing Tumour Relapse: In models where tumours had already developed and undergone conventional treatment, residual stem cells often remained, posing a high risk of recurrence. By combining a previously established treatment with CT-179, the research team was able to target these residual stem cells effectively. CT-179 prevented their re-awakening, thereby preventing tumour relapse. This "cancer interception" strategy offers a powerful new weapon against one of the most frustrating aspects of cancer treatment: recurrence.
"Our findings offer a novel strategy to target cancer stem cells, providing hope for more effective treatments against aggressive brain tumors," says Dr. Dirks, emphasizing the profound implications of this targeted approach. The use of cutting-edge genomic approaches in combination with functional experiments in preclinical models validated the efficacy and specificity of this intervention.
Collaborative Science and Broader Horizons
The impact of this discovery extends beyond the confines of a single lab. The findings from the SickKids team were corroborated by additional preclinical models in a study published simultaneously in Nature Communications from colleagues at Children’s Healthcare of Atlanta and QIMR Berghofer Medical Research Institute in Australia. This independent validation underscores the robustness and reproducibility of the results, enhancing their credibility within the scientific community.
Furthermore, the implications of this research are not limited solely to SHH medulloblastoma. The researchers believe that the mechanisms uncovered, particularly the role of cancer stem cells and their activation pathways, could be relevant to other aggressive brain cancers. Diffuse intrinsic pontine glioma (DIPG), another devastating pediatric brain tumour with an almost universally fatal prognosis, is specifically mentioned as a potential target for similar strategies. DIPG is notoriously difficult to treat due to its location in the brainstem and its highly infiltrative nature, making any new therapeutic avenue incredibly significant. The shared challenges of brain cancer stem cells across different tumour types suggest that insights gained from medulloblastoma could pave the way for broader applications.
This study also complements the Dirks Lab’s previous research in Nature, which elucidated the early stages of glioblastoma development. This consistent focus on the nascent phases of tumour growth highlights a strategic shift in cancer research: from merely treating established disease to understanding and intercepting its very genesis.
Implications for Pediatric Oncology: From Bench to Bedside
The discovery at SickKids represents a profound step forward in pediatric oncology, offering a glimmer of hope for children and families grappling with brain cancer. The concept of "cancer interception" – stopping the disease before it fully manifests or recurs – could fundamentally alter treatment paradigms.
- Precision Biology: Dr. Dirks envisions a future where this "magic bullet" for early treatment could be integrated with advanced diagnostic tools. "At SickKids, we’re already genetically testing every child with cancer to inform their diagnosis and treatments – our study goes beyond genetic testing to precision biology," he notes. This refers to understanding not just the genetic mutations present, but also the dynamic biological processes driving the cancer, allowing for hyper-targeted interventions. This level of precision could lead to highly individualized treatment plans, minimizing collateral damage to developing brains and bodies.
- Preventative Strategies: The ability to prevent tumour formation in preclinical models opens the exciting possibility of prophylactic treatments for individuals identified as being at high risk for developing SHH medulloblastoma, perhaps through genetic screening or monitoring. While this concept is still nascent, it represents a long-term vision for cancer care that moves beyond reaction to prevention.
- Reduced Toxicity and Improved Quality of Life: Current treatments for medulloblastoma, while often life-saving, carry significant long-term neurocognitive and physical side effects. A treatment strategy that intercepts cancer early or prevents recurrence by targeting specific stem cell pathways could potentially reduce the need for such aggressive, broad-spectrum therapies, thereby improving the long-term quality of life for survivors.
- Accelerated Drug Development: Identifying a specific protein (OLIG2) and a specific small molecule inhibitor (CT-179) provides clear targets for further drug development. While CT-179 is currently a research compound, the principles demonstrated could guide the development of clinical-grade drugs.
However, the path from preclinical discovery to clinical application is often long and arduous. Future research will need to expand these findings into human clinical trials to assess the safety, efficacy, and optimal dosing of such interventions in pediatric patients. This will particularly be crucial for those being monitored for relapse, offering a chance to intervene before the cancer takes hold again. The translational journey will involve rigorous testing, careful patient selection, and comprehensive monitoring to ensure that the promise of "cancer interception" can be safely and effectively realized in children.
A Collaborative Effort and a Vision for the Future
This groundbreaking research is a testament to the power of collaborative science and sustained investment in fundamental research. The study was made possible through the generous support of numerous organizations, including the Canadian Institutes of Health Research (CIHR), Ontario Institute for Cancer Research, Terry Fox Research Institute, Canadian Cancer Society, Cancer Research UK, Stand Up to Cancer, Jessica’s Footprint Foundation, Hopeful Minds Foundation, b.r.a.i.n.child, Meagan’s Walk, Garron Family Cancer Centre, the Bresler family, and SickKids Foundation. These funding bodies play an indispensable role in enabling the kind of high-risk, high-reward research that can lead to transformative medical breakthroughs.
The Dirks lab, an integral part of the Arthur and Sonia Labatt Brain Tumour Research Centre (BTRC) at SickKids, continues to be at the forefront of understanding and combating pediatric brain tumours. Their commitment to deciphering the intricate biology of these cancers, particularly the role of stem cells, is driving innovation that promises to redefine diagnosis and treatment.
"I am excited for a future where this ‘magic bullet’ for early treatment could be combined with diagnostic tests to potentially prevent the cancer from developing at all," Dr. Dirks concludes, articulating a hopeful vision that inspires the entire pediatric oncology community. The discovery of a method to stop medulloblastoma tumour growth before it starts represents not just a scientific achievement, but a beacon of hope for countless children and their families worldwide, propelling us closer to a future where childhood brain cancer is preventable and curable.
